Ceftriaxone in Non-neutropenic Fever
N/A
N/A
22 Years
N/A
22 Years
Open (Enrolling)
Both
Histiocytosis, Pediatric Patients With Cancer
Both
Histiocytosis, Pediatric Patients With Cancer
Trial Information
Ceftriaxone in Non-neutropenic Fever
Inclusion Criteria:
- Diagnosed with malignancy, Langerhans cell histiocytosis,or hemophagocytic
lymphohistiocytosis from 2007 through 2010
- Under 23 years at time of diagnosis of malignancy, Langerhans cell histiocytosis,or
hemophagocytic lymphohistiocytosis
- Treated at Monroe Carell Jr. Children's Hospital at Vanderbilt for aforementioned
diagnosis from 2007 through 2012
- While on immunosuppressive therapy with a central venous line in place had at least
one documented episode of fever (defined as ≥ 38.0°Celsius orally for over 30 minutes
or ≥ 38.3°Celsius orally x1).
Exclusion Criteria:
- Does not meet all inclusion criteria as stated above
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Retrospective
Outcome Measure:
Incidence of catheter-associated blood stream infections from all episodes of non-neutropenic fever in pediatric oncology, Langerhans cell histiocytosis or Hemophagocytic lymphohistiocytosis patients diagnosed and treated at Vanderbilt
Outcome Time Frame:
12 months
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
VICC PED1061
NCT ID:
NCT01225718
Start Date:
August 2010
Completion Date:
July 2013
Related Keywords:
- Histiocytosis
- Pediatric Patients With Cancer
- Histiocytosis
Name | Location |
|---|---|
| Monroe Carrell Jr. Children's Hospital at Vanderbilt | Nashville, Tennessee 37232 |
